There has been a lot of talk about budgets and debt ceilings in Washington this week. The negotiations – now taking place between the President and Congressional leaders are fluid, closely held, and difficult to predict. It does not take a PhD to know that Medicare and Medicaid cuts are on the table.
At AZBIO we stay in close communication with our partners at BIO, PhRMA, and AdvaMed so that we can share the latest news with our members.Continue reading
Press Release from BIO: The Leahy-Smith America Invents Act will benefit all sectors of U.S. economy
Washington, D.C. (June 23, 2011) – Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement on the passage of The Leahy-Smith America Invents Act, H.R. 1249, by the House of Representatives:
“Small biotechnology companies rely heavily on their patents to attract investment to fund the lengthy and expensive research and development process necessary to bring breakthrough medical therapies and other products to patients and consumers. Strong intellectual property protection is critical for these companies.
“The Leahy-Smith America Invents Act will bring our patent system into the 21st century. The improvements made by the bill will benefit all sectors of the national economy by enhancing patent quality and the efficiency, objectivity, predictability and transparency of the U.S. patent system.